Osuga Y, Enya K, Kudou K, Tanimoto M, Hoshiai H. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2019; 133.
The authors provided this information as a supplement to their article.
©2019 American College of Obstetricians and Gynecologists. Page 1 of 4
Appendix 1. Change in Hemoglobin Levels by Iron Preparation Use
Hemoglobin, g/dL Relugolix (n=138) Leuprorelin Acetate (n=142)
Visit
N
Change from baseline,
median (interquartile range) N
Change from baseline, median (interquartile range) Patients using oral iron preparations at baseline
Week 12 38 1.9 (1.10 to 2.90) g/dL 38 1.8 (1.10 to 2.80) g/dL
Week 24 34 1.9 (1.20 to 2.90) g/dL 35 2.1 (1.40 to 2.80) g/dL
Patients not using oral iron preparations at baseline
Week 12 91 1.0 (0.50 to 1.70) g/dL 102 1.1 (0.60 to 1.70) g/dL
Week 24 88 1.3 (0.55 to 2.30) g/dL 96 1.3 (0.65 to 2.30) g/dL
Osuga Y, Enya K, Kudou K, Tanimoto M, Hoshiai H. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2019; 133.
The authors provided this information as a supplement to their article.
©2019 American College of Obstetricians and Gynecologists. Page 2 of 4
Appendix 2. Change in Bone Metabolism Markers
Endpoint Relugolix (n=138) Leuprorelin Acetate (n=142)
Visit
N
% change from baseline,
median (interquartile range) N
% change from baseline, median (interquartile range) N-telopeptide
Week 12 138 30.7 (12.90 to 48.80) 142 28.9 (11.80 to 51.50)
Week 24 126 42.5 (21.10 to 68.20) 132 41.5 (22.55 to 68.65)
Bone-specific alkaline phosphatase
Week 12 138 24.7 (7.70 to 43.20) 142 25.6 (10.30 to 37.50)
Week 24 126 41.4 (20.60 to 71.00) 132 46.5 (23.80 to 65.80)
Osuga Y, Enya K, Kudou K, Tanimoto M, Hoshiai H. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2019; 133.
The authors provided this information as a supplement to their article.
©2019 American College of Obstetricians and Gynecologists. Page 3 of 4
Appendix 3. Change in Hormone Levels
Endpoint Relugolix (n=138) Leuprorelin Acetate (n=142)
Visit
N
Change from baseline,
median (interquartile range) N
Change from baseline, median (interquartile range) Luteinizing hormone, mIU/mL
Week 12 129 -2.5 (-3.98 to -0.93) mIU/mL 140 -3.0 (-4.24 to -2.14) mIU/mL
Week 24 122 -2.1 (-3.77 to -0.67) mIU/mL 131 -3.10 (-4.28 to -2.15) mIU/mL
Follicle stimulating hormone, mIU/mL
Week 12 129 -4.0 (-7.32 to -1.55) mIU/mL 140 -2.8 (-5.08 to -1.12) mIU/mL
Week 24 122 -3.8 (-7.14 to -1.31) mIU/mL 131 -2.1 (-4.72 to -0.94) mIU/mL
Estradiol, pg/mL
Week 12 129 -27.0 (-44.0 to -14.0) pg/mL 140 -30.0 (-48.5 to -14.0) pg/mL
Week 24 122 -31.0 (-49.0 to -16.0) pg/mL 131 -29.0 (-54.0 to -15.0) pg/mL
Progesterone, ng/mL
Week 12 129 -0.1 (-0.20 to 0.00) ng/mL 140 -0.1 (-0.20 to 0.00) ng/mL
Osuga Y, Enya K, Kudou K, Tanimoto M, Hoshiai H. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2019; 133.
The authors provided this information as a supplement to their article.
©2019 American College of Obstetricians and Gynecologists. Page 4 of 4
